Infant, children and young people's experience of health careStatus:Awaiting developmentExpected publication date: TBC
Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy [ID1587]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Children and young people with disabilities and severe complex needs: integrated health and social care supportStatus:Awaiting developmentExpected publication date: TBC
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Mirabegron for treating neurogenic detrusor overactivity in people aged 3 to 17 [TSID10730]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years [TSID10237]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Canagliflozin for treating type 2 diabetes in people 10 to 17 years [TSID11888]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Leriglitazone for treating X-linked andrenoleukodystrophy [TSID9996]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older [ID6542]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy [TSID11996]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
12 SQ-HDM SLIT for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites in children 5 to 11 years [ID6510]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [TSID12142]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Clascoterone for treating acne vulgaris in people 12 years and over [TSID12136]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Inclisiran for treating familial hypercholesterolaemia and elevated low density lipoprotein cholesterol in people 12 to 17 years [TSID12129]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Navepegritide for treating achondroplasia in people 2 to 15 years [ID6538]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tirzepatide for treating type 2 diabetes in people 10 to 17 years [TSID12131]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ritlecitinib for treating non-segmental vitiligo in people 12 years and over [TSID12187]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Axatilimab for treating active chronic graft-versus-host disease after 2 or more systemic treatments in people 2 years and over [TSID12189]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [TSID12168]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rocatinlimab for treating moderate to severe atopic dermatitis in people 12 years and over [ID6565]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC